BOT announced positive results from its BTX 1801 Phase 2a nasal decolonisation proof of concept study. We upgrade to SPEC BUY (prior HOLD) as these results highlight CBD’s potential as a new treatment for resistant bacteria. To access the full report please log in under the Client Area at the bottom of this page. Argonaut’sRead more
Argonaut | The Natural Choice in Resources.
© 2024 Argonaut.